Delivery Order SPE2DB24D2101-SPE2DB25FKPXK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a delivery order valued at $1,279.87 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count package) on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,004.76 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitive delivery order utilizes firm fixed pricing and is not supported by a set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under...
- The Defense Logistics Agency awarded a $16,427.01 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Gemtesa 75 mg tablets (90 count). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) valued at $7,179.96. This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a delivery order, this award represents a single fulfillment action under a larger contracting vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $48,927.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,148.50 for 90-tablet supplies of Gemtesa 75 mg tablets under a firm fixed-price contract. The award, made on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a competitively awarded, non-set-aside procurement. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $1,389.38. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $1,722.87. This firm fixed-price delivery order, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Gemtesa 75 mg tablets (30-count packages) with a contract ceiling value of $4,316.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPXKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on September 24, 2025, with a ceiling value of $15,126.73. This is a firm fixed-price delivery order with no set-aside designation, executed competitively against the vendor's larger indefinite delivery contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order falls under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare systems worldwide. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, with a substantial portfolio of contract awards demonstrating its capability to fulfill diverse pharmaceutical and medical supply requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.1k | 9/24/25 |